<DOC>
	<DOCNO>NCT00819234</DOCNO>
	<brief_summary>Study DFA102E extension Study DFA102 , include 28-week treatment period randomize study medication . The purpose extension study examine long-term ( 1 year ) safety , tolerability , effect body weight treatment pramlintide metreleptin , administer separate subcutaneous ( SC ) injection , obese overweight subject .</brief_summary>
	<brief_title>Extension Study Protocol DFA102 Examine Long-Term Safety , Tolerability , Effect Body Weight Pramlintide Administered Combination With Metreleptin</brief_title>
	<detailed_description />
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Pramlintide</mesh_term>
	<mesh_term>Islet Amyloid Polypeptide</mesh_term>
	<criteria>Completed Study DFA102 , include procedure require Study Termination visit , without major protocol deviation Male , female meet follow criterion : 1 . Has negative urine pregnancy test result Study start ( applicable hysterectomized female ) 2 . If childbearing potential must practice willing continue practice appropriate birth control entire duration study Able read , understand , sign Informed Consent Form ( ICF ) applicable , Authorization Use Disclose Protected Health Information Form , answer study questionnaire , communicate investigator , understand comply protocol requirement Is expect require undergo treatment exclusionary medication . Is undesirable study participant judge investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Leptin</keyword>
	<keyword>Pramlintide</keyword>
	<keyword>Obese</keyword>
	<keyword>Symlin</keyword>
	<keyword>Amylin</keyword>
</DOC>